ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Ratio Therapeutics raised $70 million in Series C funding. The financing will support the company's radiopharmaceutical development programs. The round advances Ratio Therapeutics' work in targeted cancer therapies.
Tap to vote and see what everyone thinks.
Summary by ByteBrief